🏥 Health & Medicine
GRAIL's Galleri test looks for the signal of dozens of cancers from a single blood draw — potentially catching disease years before symptoms. The science is real and the market would be enormous. But revenue is tiny, losses are huge, and the whole thesis hinges on two things GRAIL doesn't yet have: FDA approval and broad insurance coverage.
Updated · Q1 2026 · March 2026
$150M / yr revenue · public since 2024
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time GRAIL files a new report, the chapters get updated here.